PTH actions on early cells of the osteoblast lineage

PTH 对成骨细胞谱系早期细胞的作用

基本信息

  • 批准号:
    10207597
  • 负责人:
  • 金额:
    $ 40.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-01 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

Parathyroid hormone (PTH), whether administered intermittently to treat osteoporosis, or administered continuously in rodent experiments, increases bone formation rate. While osteoblasts, osteocytes, and bone lining cells contribute to the PTH response, the role of osteoblast precursors in the PTH response is poorly understood. We have used expression of Sox9, a gene expressed in many stem cell types, to mark early cells in the osteoblast lineage and to understand how PTH affects these cells. In Aim 1, we will determine the signaling pathways inside osteoblast precursors that are activated downstream from the PTH receptor in order to increase the number of these precursors. Because Gs, the heterotrimeric G protein, is an important signaling relay downstream of the PTH receptor in mature osteoblasts and osteocytes, we will knockout Gsa in Sox9-expressing osteoblast precursors and their descendants. Because mice with a mutant PTH receptor (so- called DSEL receptor) that cannot activate Gq/11 have abnormal bone, we will determine whether PTH increases the number of osteoblast precursors in DSEL receptor mice in the same way that PTH does in wild type mice. Because salt-induced kinases (SIKs) are prominent regulatory targets of PTH signaling in osteocytes, we will determine whether inhibition of SIKs is an important strategy downstream of activation of Gsa in the PTH-induced increase in the number of osteoblast precursors. In Aim 2, we will address the heterogeneity of the early cells of the osteoblast lineage. Osteoblast precursors can be found in the growth plate, bone marrow, and periosteum. We will use lineage tracing in Aim 2A to determine whether growth plate osteoblast precursors (marked with PTHrPcreERt) become Sox9-expressing cells in the marrow and whether Sox9 marked cells become CXCL12-abundant reticular (CAR) cells in the marrow. Further, we have found that Sox9-marked cells in the metaphysis, the endosteum and periosteum have strikingly different paths to osteogenesis. To determine these paths, and also to compare Sox9-marked paths with those marked by growth plate stem cells and marrow CAR cells, we will use single cell RNA sequencing in collaboration with Dr. Alexandra-Chloé Villani, a leader in this field in Aim 2B. The characterization of the genetic makeup of individual cells will allow us to define the variety of distinct fates of skeletal stem cells and the signaling molecules/transcription factors that regulate these cells. In Aim 3, we will use these same methods to determine how PTH increases the numbers of cells descended from skeletal precursors and how the cellular pathways change when Gs signaling is blocked in these cells. Single cell RNA sequencing will be used to determine the mechanisms downstream of the pathways established in Aim 1 that PTH uses to increase the numbers of osteoblast precursors. Thus, we will clarify the relationships between the varieties of skeletal stem cells and how PTH changes the pathways used by skeletal precursors.
甲状旁腺激素(PTH),无论是间歇性给药治疗骨质疏松症,还是 在啮齿类动物实验中,持续增加骨形成率。而成骨细胞骨细胞和骨 衬里细胞有助于PTH反应,成骨细胞前体在PTH反应中的作用很差 明白我们使用Sox 9基因的表达来标记早期细胞,Sox 9基因在许多干细胞类型中表达 并了解甲状旁腺素如何影响这些细胞。在目标1中,我们将确定 成骨细胞前体细胞内的信号通路,其在PTH受体下游被激活, 来增加这些前体的数量。因为Gs,异三聚体G蛋白,是一个重要的 成熟成骨细胞和骨细胞中PTH受体下游的信号传递,我们将敲除Gsa, 表达sox 9的成骨细胞前体及其后代。因为具有突变型PTH受体的小鼠(因此- 称为DSEL受体)不能激活Gq/11有异常的骨,我们将确定是否PTH 增加DSEL受体小鼠中成骨细胞前体的数量,与野生型PTH相同。 型小鼠。由于盐诱导的激酶(SIKs)是PTH信号传导的主要调节靶点, 骨细胞,我们将确定是否抑制SIKs是一个重要的策略下游的激活, Gsa在PTH诱导的成骨细胞前体细胞数量增加。在目标2中,我们将讨论 成骨细胞系早期细胞的异质性。成骨细胞前体可以在生长中找到。 骨板骨髓和骨膜我们将在Aim 2A中使用谱系追踪来确定生长板是否 成骨细胞前体(标记为PTHrPcreER t)在骨髓中成为Sox 9表达细胞, Sox 9标记的细胞在骨髓中变成富含CXCL 12的网状(CAR)细胞。此外,我们还发现 Sox 9标记的细胞在干骺端、骨内膜和骨膜中具有显著不同的途径, 成骨为了确定这些路径,并将Sox 9标记的路径与由 生长板干细胞和骨髓CAR细胞,我们将使用单细胞RNA测序与Dr。 Alexandra-Chloé Villani是Aim 2B这一领域的领导者。基因组成的表征 单个细胞将使我们能够确定骨骼干细胞的不同命运和信号转导的多样性。 调节这些细胞的分子/转录因子。在目标3中,我们将使用这些相同的方法来 确定PTH如何增加骨骼前体细胞的数量,以及细胞如何 当Gs信号传导在这些细胞中被阻断时,通路发生变化。单细胞RNA测序将用于 确定目标1中建立的通路下游的机制,PTH用于增加 成骨细胞前体的数量。因此,我们将阐明骨骼茎品种之间的关系 细胞以及PTH如何改变骨骼前体细胞使用的途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(27)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HENRY M. KRONENBERG其他文献

HENRY M. KRONENBERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HENRY M. KRONENBERG', 18)}}的其他基金

The role of osteoblast progenitors in response to bone anabolic agents
成骨细胞祖细胞对骨合成代谢剂的反应的作用
  • 批准号:
    10404415
  • 财政年份:
    2023
  • 资助金额:
    $ 40.85万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10451721
  • 财政年份:
    2019
  • 资助金额:
    $ 40.85万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10183170
  • 财政年份:
    2019
  • 资助金额:
    $ 40.85万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10626807
  • 财政年份:
    2019
  • 资助金额:
    $ 40.85万
  • 项目类别:
CENTER FOR SKELETAL RESEARCH
骨骼研究中心
  • 批准号:
    9285601
  • 财政年份:
    2014
  • 资助金额:
    $ 40.85万
  • 项目类别:
CENTER FOR SKELETAL RESEARCH
骨骼研究中心
  • 批准号:
    8853820
  • 财政年份:
    2014
  • 资助金额:
    $ 40.85万
  • 项目类别:
CENTER FOR SKELETAL RESEARCH
骨骼研究中心
  • 批准号:
    8693238
  • 财政年份:
    2014
  • 资助金额:
    $ 40.85万
  • 项目类别:
Genetic Analysis of Second Messengers in PTH Signaling in Bone
骨 PTH 信号传导第二信使的遗传分析
  • 批准号:
    7627067
  • 财政年份:
    2008
  • 资助金额:
    $ 40.85万
  • 项目类别:
Functions of PTH/PHTrP Receptor, PTHrP and PTH in vivo
PTH/PHTrP 受体、PTHrP 和体内 PTH 的功能
  • 批准号:
    7432428
  • 财政年份:
    2007
  • 资助金额:
    $ 40.85万
  • 项目类别:
Role of PLC in PTH Signaling: Mutant Receptors in Vivo
PLC 在 PTH 信号传导中的作用:体内突变受体
  • 批准号:
    7325709
  • 财政年份:
    2006
  • 资助金额:
    $ 40.85万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 40.85万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.85万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 40.85万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.85万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 40.85万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.85万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 40.85万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 40.85万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 40.85万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.85万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了